Trang chủ › U tủy xương đa phát › Massachusetts › Boston
Thử nghiệm lâm sàng cho U tủy xương đa phát tại Boston, MA
45 nghiên cứu cho U tủy xương đa phát đang tìm kiếm người tham gia tại các cơ sở ở Boston và vùng lân cận (bán kính khoảng 30 dặm). Mở nghiên cứu để xem tiêu chí tham gia và cách liên hệ với đội ngũ nghiên cứu.
Văn bản nghiên cứu chính thức (Tiếng Anh)
Đang tuyển dụng cho một nghiên cứu? Đưa tin của bạn lên đầu trang này — $99 trong 30 ngày →
MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)
Đang tuyểnGiai đoạn 3
- Beth Israel Deaconess Medical Center, Boston
- BIDMC Research Pharmacy, Boston
A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Participants With Multiple Myeloma That is Resistant to Current Standard of Care Treatments
Đang tuyểnGiai đoạn 1
- Dana Farber/Harvard Cancer Center, Boston
A Study to Compare Linvoseltamab and Daratumumab Treatment in High-Risk Smoldering Multiple Myeloma (HR-SMM)
Đang tuyểnGiai đoạn 3
- Dana Farber / Harvard Cancer Center, Boston
A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel
Đang tuyểnGiai đoạn 4
- Dana Farber Cancer Institute, Boston
- Beth Israel Deaconess Medical Center, Boston
- Massachusetts General Hospital, Boston
A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
Đang tuyểnGiai đoạn 3
- Dana Farber Cancer Institute, Boston
- Boston University Medical Center, Boston
- Beth Israel Deaconess Medical Center, Boston
Pivotal Study to Validate a Novel System to Non-Invasively Detect Severe Neutropenia
Đang tuyểnNghiên cứu quan sát
- Massachussetts General Hospital, Boston
Systemic Anti-Cancer Therapy Dose Modifications for Individuals With Duffy Null Phenotype
Đang tuyểnGiai đoạn 1
- Dana-Farber Cancer Institute, Boston
ELEVATE-MM: Elotuzumab, Iberdomide and Dexamethasone Post Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma
Đang tuyểnGiai đoạn 1
- Brigham and Women's Hospital, Boston
- Beth Israel Deaconess Medical Center, Boston
- Dana Farber Cancer Institute, Boston
Study to Assess Safety and Tolerability of OPN-6602 in Subjects With Relapsed and/or Refractory Multiple Myeloma
Đang tuyểnGiai đoạn 1
- Dana Farber Cancer Institute, Boston
A Study to Evaluate the Efficacy of Cemsidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma
Đang tuyểnGiai đoạn 2
- Beth Israel Deaconess Medical Center, Boston
- Dana Farber Cancer Institute, Boston
- Massachusetts General Hospital, Boston
AZD0305 as Monotherapy or in Combination With Anticancer Agents in Participants With Multiple Myeloma
Đang tuyểnGiai đoạn 1/2
- Research Site, Boston
A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)
Đang tuyểnGiai đoạn 3
- Boston Medical Center, Boston
A Study to Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)
Đang tuyểnGiai đoạn 1/2
- Dana-Farber Cancer Institute /ID# 271846, Boston
A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma
Đang tuyểnGiai đoạn 1
- Massachusetts General Hospital, Boston
- Dana-Farber Cancer Institute, Boston
A Phase III, Multicentre Study to Evaluate Consolidation Treatment With AZD0120 Compared With ASCT, in Participants With Newly Diagnosed Multiple Myeloma Who Are Transplant Eligible (DURGA-6).
Đang tuyểnGiai đoạn 3
- Research Site, Boston
- Research Site, Boston
D2 - Isa-Iber-VD Induction, Followed by Risk & Response Adapted Consolidation & Maintenance, in Transplant-Eligible NDMM
Đang tuyểnGiai đoạn 3
- Beth Israel Deaconess Medical Center (BIDMC), Boston
- Brigham and Women's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
AZD0120 in Relapsed/Refractory Multiple Myeloma (DURGA-1)
Đang tuyểnGiai đoạn 1/2
- Research Site, Boston
- Research Site, Boston
Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma
Đang tuyểnGiai đoạn 2
- Massachusetts General Hospital, Boston
- Dana-Farber Cancer Institute, Boston
A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)
Đang tuyểnGiai đoạn 3
- Research Site, Boston
- Research Site, Boston
A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
Đang tuyểnGiai đoạn 3
- Tufts Medical Center, Boston
Study of Belantamab Mafodotin With Carfilzomib, Pomalidomide, and Dexamethasone in Relapsed Multiple Myeloma
Đang tuyểnGiai đoạn 2
- Beth Israel Deaconess Medical Center, Boston
A Study of mRNA-2808 in Participants With Relapsed or Refractory Multiple Myeloma
Đang tuyểnGiai đoạn 1/2
- Mass General Brigham, Boston
ELISA in Relapsed/Refractory MM
Đang tuyểnGiai đoạn 2
- Massachusetts General Hospital, Boston
- Beth Israel Deaconess Medical Center, Boston
- Dana Farber Cancer Institute, Boston
Elranatamab in R/R Multiple Myeloma
Đang tuyểnGiai đoạn 2
- Massachusetts General Hospital, Boston
- Dana-Farber Cancer Institute, Boston
- Beth-Israel Deaconess Medical Center, Boston
Study of SIM0500 Alone in Participants With Relapsed or Refractory Multiple Myeloma
Đang tuyểnGiai đoạn 1
- Dana Farber Cancer institution, Boston
A Study to Evaluate a Novel Gene Therapy in Patients With Relapsed and Refractory Multiple Myeloma
Đang tuyểnGiai đoạn 1
- Massachusetts General Hospital, Boston
Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial
Đang tuyểnGiai đoạn 3
- Tufts Medical Center, Boston
A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments
Đang tuyểnGiai đoạn 1/2
- GSK Investigational Site, Boston
A Trial to Learn if Linvoseltamab is Safe and Works in Adults With Relapsed or Refractory Systemic Light Chain Amyloidosis (AL Amyloidosis)
Đang tuyểnGiai đoạn 1/2
- Boston Medical Center, Boston
Immuno-PRISM (PRecision Intervention Smoldering Myeloma)
Đang tuyểnGiai đoạn 2
- Dana Farber Cancer Institute, Boston
A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of Arlocabtagene Autoleucel (BMS-986393) in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma
Đang tuyểnGiai đoạn 1
- Beth Israel Deaconess Medical Center, Boston
- Dana-Farber Cancer Institute, Boston
Selinexor and Backbone Treatments of Multiple Myeloma Patients
Đang tuyểnGiai đoạn 1/2
- Dana Farber Cancer Institute, Boston
Low-Dose Radiotherapy in Treating Painful Bone Metastases in Patients With Multiple Myeloma
Đang tuyển
- Dana-Farber Cancer Institute, Boston
DC/MM Fusion Vaccine With BCMA CAR-T in R/R MM
Đang tuyểnGiai đoạn 1
- Beth Israel Deaconess Medical Center, Boston
A Phase 1 Study of Vaccination With Dendritic Cell (DC)/Multiple Myeloma (MM) Fusions in Combination With Elranatamab in Relapsed or Refractory Multiple Myeloma
Đang tuyểnGiai đoạn 1
- Beth Israel Deaconess Medical Center, Boston
- Dana-Farber Cancer Institute, Boston
Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.
Đang tuyểnGiai đoạn 1
- Dana Farber Cancer Institute, Boston
Defining the Role of Palliative carE for Patients With Hematologic Malignancies Undergoing Adoptive CEllular Therapy
Đang tuyển
- Massachusetts General Hospital Cancer Center, Boston
Mezigdomide and Talquetamab in Relapsed and Refractory Multiple Myeloma
Đang tuyểnGiai đoạn 1
- Massachusetts General Hospital, Boston
- Beth Israel Deaconess Medical Center, Boston
- Dana-Farber Cancer Institute, Boston
Study of ISB 2001 in Relapsed/Refractory Multiple Myeloma (TRIgnite-1)
Đang tuyểnGiai đoạn 1
- Beth Israel Deaconess Medical Center, Boston
A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
Đang tuyểnGiai đoạn 1/2
- Massachusetts General Hospital, Boston
A Study to Assess BMS-986453 in Participants With Relapsed and/or Refractory Multiple Myeloma
Đang tuyểnGiai đoạn 1
- Dana-Farber Cancer Institute, Boston
Prehabilitation Exercise Training in Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation
Đang tuyển
- Dana Farber Cancer Institute, Boston
- Dana-Farber Cancer Institute, Boston
Isatuximab, Bela Maf, Pom, and Dex in Relapsed/Refractory Multiple Myeloma
Đang tuyểnGiai đoạn 2
- Massachusetts General Hospital, Boston
- Dana-Farber Cancer Institute, Boston
Collection of Samples and Clinical Data From Patients With Amyloid Diseases
Đang tuyểnNghiên cứu quan sát
- Boston University Cancer Research Center, Boston
A Study to Evaluate Safety, Drug Levels and Effectiveness of CC-92480 (BMS-986348) in Combination With Other Treatments in Participants With Relapsed or Refractory Multiple Myeloma
Đang tuyểnGiai đoạn 1/2
- Dana-Farber Cancer Institute, Boston
Thử nghiệm cho U tủy xương đa phát tại các thành phố khác
- New York City, NY59 nghiên cứu
- Atlanta, GA42 nghiên cứu
- Houston, TX39 nghiên cứu
- Durham, NC36 nghiên cứu
- Nashville, TN31 nghiên cứu
- Denver, CO26 nghiên cứu
- St. Louis, MO26 nghiên cứu
- Rochester, MN25 nghiên cứu
- Columbus, OH25 nghiên cứu
- Chicago, IL24 nghiên cứu
- Milwaukee, WI23 nghiên cứu
- Baldwin Park, CA23 nghiên cứu
Các nghiên cứu khác tại Boston
- Ung thư vú110 nghiên cứu
- Ung thư (mọi loại)90 nghiên cứu
- Ung thư phổi không tế bào nhỏ87 nghiên cứu
- Ung thư phổi63 nghiên cứu
- Ung thư đại trực tràng62 nghiên cứu
- Ung thư buồng trứng62 nghiên cứu
- Ung thư di căn61 nghiên cứu
- Ung thư tuyến tiền liệt56 nghiên cứu
- Ung thư nội mạc tử cung51 nghiên cứu
- Trầm cảm50 nghiên cứu
- Suy tim46 nghiên cứu
- Bạch cầu tủy cấp44 nghiên cứu
Nguồn dữ liệu từ ClinicalTrials.gov, cập nhật ngày 15 thg 11, 2026. Mỗi nghiên cứu có tiêu chí riêng; đội ngũ nghiên cứu sẽ quyết định ai đủ điều kiện tham gia.